William F Maguire

8PUBLICATIONS
50CO-AUTHORS
Molecular targetsRadiation therapyPharmacogenomicsCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (8)

|Aug 12, 2026
FDA Approval Summary: Erdafitinib for FGFR3-Altered Locally Advanced or Metastatic Urothelial Carcinoma.

|Jul 23, 2026
Into the Unknown: Regulatory Perspective on Identifying Optimized Dosages of Oncology Radiopharmaceutical Therapies.

|Jul 17, 2025
FDA Approval Summary: Niraparib plus Abiraterone Acetate Fixed-Dose Combination for BRCA-Mutated Metastatic Castration-Resistant Prostate Cancer.

William F Maguire, Dow-Chung Chi, Sundeep Agrawal

|Sep 04, 2024
FDA Approval Summary: Enfortumab Vedotin plus Pembrolizumab for Locally Advanced or Metastatic Urothelial Carcinoma.

Michael H Brave, William F Maguire, Chana Weinstock

|Aug 29, 2024
False-Positive Circulating Tumor DNA Results Do Not Explain Lack of Efficacy for PARP Inhibitors in Patients With Castration-Resistant Prostate Cancer Harboring ATM and CHEK2 Mutations.

Jaleh Fallah, Jianjin Xu, Hee-Koung Joeng

|Mar 14, 2024
Efficacy of Poly(ADP-ribose) Polymerase Inhibitors by Individual Genes in Homologous Recombination Repair Gene-Mutated Metastatic Castration-Resistant Prostate Cancer: A US Food and Drug Administration Pooled Analysis.

Jaleh Fallah, Jianjin Xu, Chana Weinstock

Pageof 2

Frequent Collaborators

6 joint publications

Laleh Amiri-Kordestani

5 joint publications

Xin Gao

5 joint publications

Elaine Chang

4 joint publications

Daniel L Suzman